T-Cell type acute lymphoblastic leukemia following cyclosporin A therapy for aplastic anemia.
Cyclosporin A (CsA) is used to prevent rejection in transplantation and to treat autoimmune and hematologic diseases such as aplastic anemia. However, the tumor growth-promoting effect of CsA remains controversial. We report the case of a 24-year-old man who developed acute lymphoblastic leukemia of precursor-T-cell origin after 75 months of treatment with CsA for aplastic anemia. The surface antigen phenotype of his leukemic cells was CD2+, CD3+, CD5+, CD7+, CD4-, CD8-, CD10-, CD20-, CD34-, CD41-, and CD56-. Southern blot analysis revealed a monoclonal rearrangement of T-cell receptor-Jgamma nongermline fragments in HindIII digestion.
Hirose
Y
Y
Department of Internal Medicine, Kanazawa Medical University, Ishikawa, Japan. y-hirose@kanazawa-med.ac.jp
Masaki
Y
Y
Ebata
K
K
Okada
J
J
Kim
C G
CG
Ogawa
N
N
Wano
Y
Y
Sugai
S
S
D000293:Adolescent; D000741:Anemia, Aplastic / Q000150:complications / Q000188:drug therapy*; D002471:Cell Transformation, Neoplastic / Q000187:drug effects; D002999:Clone Cells; D016572:Cyclosporine / Q000008:administration & dosage / Q000009:adverse effects*; D015321:Gene Rearrangement; D006801:Humans; D016130:Immunophenotyping; D015458:Leukemia, T-Cell / Q000139:chemically induced* / Q000473:pathology; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000139:chemically induced* / Q000473:pathology; D011948:Receptors, Antigen, T-Cell / Q000235:genetics
D011948:Receptors, Antigen, T-Cell; D016572:Cyclosporine